How to Get Ozempic Covered by Insurance

Summary: Ozempic gets covered when the prescription codes for type 2 diabetes, the chart shows an A1C at or above 6.5% with a documented metformin trial, and the prior authorization packet anticipates the insurer's checklist before they ask for it.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: Ozempic gets covered when the prescription is for type 2 diabetes, the chart shows an A1C at or above 6.5%, and the prior authorization packet documents a prior trial of metformin or a clinical reason metformin is off the table. Off-label weight loss prescriptions for Ozempic almost always get denied. The Wegovy path exists for that case, and it is the better fight to pick.

This page walks through the diagnosis you need, the prescriber move that matters, the exact paperwork that wins prior authorizations, the appeal process when you lose round one, and what to do if your plan flatly refuses.

Why the indication on the prescription decides everything

Ozempic and Wegovy are the same molecule (semaglutide), packaged into different products with different FDA labels ^[1]. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction in adults with T2D and known cardiovascular disease. Wegovy is approved for chronic weight management at higher doses. Insurers treat them as two separate coverage questions.

Coverage for Ozempic with a type 2 diabetes diagnosis is widespread across commercial plans, Medicare Part D, and most state Medicaid programs. Coverage for Ozempic prescribed off-label for weight loss is rare and most plans exclude it outright. The single most important fact about your prescription is what is in the diagnosis field. The ICD-10 code matters as much as the drug name.

The diagnosis codes that determine the outcome

Two code families drive insurance decisions on semaglutide:

The takeaway: a prescription with E11.9 (type 2 diabetes without complications) in the diagnosis field is the version that gets paid. A prescription with E66.01 (morbid obesity) is the version that gets bounced.

Step 1: Confirm the type 2 diabetes diagnosis

If you have not been formally diagnosed with T2D, this is where you start. The American Diabetes Association recognizes any one of four lab criteria as sufficient for a diabetes diagnosis ^[2]:

• HbA1c at or above 6.5% on a standardized assay
• Fasting plasma glucose at or above 126 mg/dL after at least 8 hours of no caloric intake
• 2-hour plasma glucose at or above 200 mg/dL during a 75 g oral glucose tolerance test
• Random plasma glucose at or above 200 mg/dL in a patient with classic hyperglycemia symptoms or hyperglycemic crisis

In the absence of clear symptoms, the criteria should be confirmed by repeat testing. If a single elevated A1C is followed by a repeat A1C also at or above 6.5%, that is the diagnosis. Get the labs into your chart. Insurance prior authorization reviewers look for the lab value, not just the diagnosis code.

If your A1C is between 5.7% and 6.4%, that is prediabetes. Insurance will not cover Ozempic for prediabetes. Medicare cannot cover Ozempic for prediabetes either. Coverage requires a confirmed T2D diagnosis. If you are sitting at 6.3% and your doctor is comfortable with a trial of metformin first, that is the correct clinical path anyway, and twelve months later if the A1C has climbed past 6.5%, the door opens.

What about insulin resistance or PCOS?

Insulin resistance is not an ICD-10 condition with a code that maps to GLP-1 coverage. The closest billable codes (R73.09, E88.81) do not unlock Ozempic on any major formulary we have reviewed. PCOS with insulin resistance has the same problem. If insulin resistance has progressed to confirmed T2D, you are back on the covered path. If it has not, off-label use is the only mechanism, and you should expect denial.

Step 2: Get the right prescriber

A primary care physician can prescribe Ozempic. So can an endocrinologist, a nurse practitioner, and a physician assistant, depending on state scope-of-practice rules. A nutritionist or dietitian cannot prescribe Ozempic. They do not have prescriptive authority. If a website implies a nutritionist will get you a prescription, what they mean is a licensed prescriber on the same platform writes it.

The prescriber's specialty matters in two specific ways:

1. Some plans require an endocrinologist signature for prior authorization. This is more common on plans with strict step-therapy protocols. Check your plan's formulary document or call member services and ask "Does the Ozempic prior authorization require a specialist prescriber?" If yes, get the endocrinology referral before the PA goes in.
2. Telehealth prescribers vary in their willingness to code for T2D. A telehealth platform that markets weight-loss programs is, by default, going to code for weight loss. If you have a T2D diagnosis and want Ozempic covered, you need a prescriber who will read your labs, accept the T2D diagnosis, and write the prescription with an E11.x code. Bring your A1C, your prior medication trials, and your insurance card to the first visit.

Step 3: The prior authorization fight

Most commercial insurance plans require prior authorization (PA) for Ozempic. The PA exists because Ozempic's list price is roughly $1,000 per month and the insurer wants documented medical necessity before they pay. The PA is also where most coverage gets won or lost.

The documentation that wins

A clean prior authorization packet contains:

• Lab evidence of the diagnosis. The most recent A1C, ideally with one or two prior values showing a trend. Fasting glucose if relevant. Date and lab name on every result.
• A history of prior medications. Metformin is the universal first-line drug for T2D, and most plans require documentation of a metformin trial before approving a GLP-1. Document the dose, the duration (the standard ask is at least three months at the maximum tolerated dose), and the outcome. "Patient achieved A1C 8.2% on metformin 2000 mg daily for six months" is what reviewers want to read. If metformin caused intolerable GI side effects or is contraindicated (eGFR below 30, contrast study scheduled), document that explicitly with the date and the specific reason.
• Comorbidity documentation if T2D plus obesity. Hypertension, dyslipidemia, sleep apnea, established cardiovascular disease, NAFLD. Each comorbidity strengthens the medical necessity argument. The American Diabetes Association's guidelines recommend GLP-1s preferentially in T2D patients with established cardiovascular disease, so cardiovascular history is weight-bearing on the PA.
• BMI on the same chart note. If the patient also has obesity (BMI at or above 30, or at or above 27 with weight-related comorbidity), the chart should reflect it. It strengthens the case for a GLP-1 over older drug classes.
• A short letter of medical necessity from the prescriber. Two paragraphs. State the diagnosis with lab values. State the prior medications tried. State why Ozempic is the right choice for this patient (failed step therapy, cardiovascular risk, weight comorbidity). Sign and date.

What insurers actually check

Common prior authorization criteria across major plans:

• Confirmed T2D diagnosis (A1C at or above 6.5%, or matching ADA criteria)
• Patient is age 18 or older
• Documented trial and failure or intolerance of metformin, or documented contraindication
• For some plans, an A1C above a threshold (often 7.0% or 7.5%) while on prior therapy
• For some plans, a trial of an additional oral agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) before GLP-1 approval
• Prescription written by an appropriately credentialed prescriber

If the packet you submit answers every one of those bullet points before the insurer has to ask, the approval comes back in days, not weeks. The submission method varies (CoverMyMeds portal, fax, payer-specific portal). Your prescriber's office handles submission. Get the case reference number from the office before you leave so you can call and check status.

Timelines

Standard prior authorization: 5 to 15 business days. Expedited (urgent) prior authorization, if the prescriber documents medical urgency: 24 to 72 hours. If the time runs and you have not heard back, call the insurer's pharmacy benefits line and ask the status by reference number.

Step 4: The appeal when you get denied

Roughly one in three commercial PA submissions for GLP-1 medications come back denied on first pass. Many of those denials are overturned on appeal. Read the denial letter twice, identify the precise reason cited, and answer that reason directly. Generic appeal letters lose. Specific ones win.

The most common denial reasons and how to answer each:

"Step therapy not completed"

The plan wants documentation of a failed trial of a cheaper agent before authorizing Ozempic. The answer is the medication history you should already have on file. Submit a chart note listing each prior diabetes drug, the dose, the duration, the dates, the A1C while on the drug, and the reason for discontinuation. If you have not tried the step therapy drug, the choices are: try it now and re-apply in 3 to 6 months, or document a contraindication (allergy, intolerance, drug interaction, kidney function) that makes the step drug inappropriate.

"Insufficient documentation of diagnosis"

The plan wants the labs in the file. Submit the A1C results with lab name, date, and value. If the diagnosis is supported by fasting glucose or OGTT rather than A1C, submit those instead. A diagnosis code without underlying lab evidence is the most common documentation gap.

"Clinical criteria not met"

This usually means the A1C is not above the plan's threshold while on current therapy. If the A1C has climbed since the original submission, re-submit with the new value. If your A1C is well controlled on current therapy and the plan only covers GLP-1s for uncontrolled diabetes, the appeal is uphill. The clinical argument here is that early GLP-1 therapy reduces cardiovascular risk and is recommended by ADA guidelines for patients with established cardiovascular disease regardless of A1C ^[2]. Attach the relevant guideline excerpt.

"Non-formulary" or "Drug not covered"

The plan does not have Ozempic on the formulary at any tier. This is harder to appeal than a tier-restriction denial, but a formulary exception request is the procedural answer. The argument is medical necessity for the specific patient combined with documented failure or intolerance of the plan's preferred GLP-1 alternatives (Trulicity, Victoza, Bydureon). If you have not tried the preferred drug, the plan will say try it first.

"Off-label use"

The diagnosis on the prescription is obesity or prediabetes, not T2D. This denial is almost impossible to overturn for Ozempic, because the FDA label is the line the insurer will not cross. The correct move is to switch the conversation to Wegovy if weight loss is the goal.

How to actually submit the appeal

Internal appeal: write a letter, attach supporting documentation, send certified mail or a confirmed payer portal upload. Address the specific denial reason cited. Include the denial reference number. Submit within the deadline (commonly 60 to 180 days from the denial date; check the letter).

Peer-to-peer review: your prescriber can request a phone call with the insurer's medical director to discuss the case. These calls resolve many borderline denials. Ask your prescriber to request one before or alongside the written appeal.

External review: if the internal appeal fails, federal law gives you the right to an independent external review for most employer-sponsored and ACA marketplace plans ^[5]. The external reviewer is not affiliated with the insurer and their decision is binding. State insurance departments coordinate the process. The denial letter explains how to request it.

Step 5: If the appeal fails

When every appeal channel closes, the choices narrow to alternatives.

Switch to a different covered GLP-1

If your plan denies Ozempic but covers Trulicity (dulaglutide), Victoza (liraglutide), or Mounjaro (tirzepatide) for T2D, ask your prescriber to switch. All four are GLP-1 receptor agonists or dual agonists with similar mechanism and overlapping evidence in T2D. Mounjaro tends to produce larger A1C reductions than Ozempic in head-to-head data. Trulicity is once-weekly like Ozempic and has been on formularies longer. Victoza is daily. The right choice depends on what your plan covers, which the formulary or a member services call will tell you.

Pivot to Wegovy if weight loss is the goal

If you are pre-diabetic or non-diabetic and you want semaglutide for weight loss, Wegovy is the on-label option ^[1]. Some employer-sponsored plans cover Wegovy as part of a weight-management benefit. Most plans require documentation of BMI at or above 30, or BMI at or above 27 with a weight-related comorbidity, plus a documented attempt at lifestyle modification (often a structured program of three to six months). Wegovy coverage is plan-specific. Call and ask whether anti-obesity medications are part of your benefits before you start the prescribing visit.

Use the manufacturer savings card

For commercially insured patients whose plan covers Ozempic but with high cost-sharing, the Novo Nordisk Ozempic Savings Card reduces the copay to as little as $25 per month for up to 24 fills. It is not usable with Medicare, Medicaid, TRICARE, or VA coverage. Eligibility runs through ozempic.com.

Cash-pay and compounded options

Without insurance, Ozempic's list price is roughly $1,000 per month at retail pharmacies, though Novo Nordisk launched a direct-to-patient cash price in 2025 that runs $349 per month for the 0.25 mg, 0.5 mg, and 1 mg doses and $499 per month for the 2 mg dose. Compounded semaglutide, available through some telehealth platforms while specific shortage criteria apply, runs $150 to $300 per month. The legal status of compounded semaglutide tightened in 2024 when the FDA removed semaglutide from its drug shortage list, which limits compounding to specific clinical scenarios. Confirm the legal basis before you order.

Coverage by major payer

The patterns below summarize how the largest US insurers handle Ozempic. Plan-specific details vary by employer group and product line, so confirm with member services before assuming.

Commercial plans (employer-sponsored and marketplace)

If you are on a self-funded employer plan, the formulary and PA criteria are set by the employer, not by the carrier name on your card. Ask HR for the pharmacy benefits manager's formulary document.

Medicare Part D

Medicare Part D covers Ozempic for type 2 diabetes. It has since the drug was approved in 2017. The CMS Part D benefit covers FDA-approved indications, and the T2D indication qualifies ^[3]. Most Part D plans put Ozempic on tier 3 or tier 4 with a prior authorization requirement; the PA criteria mirror commercial criteria (confirmed T2D, A1C threshold, step therapy with metformin).

Medicare cannot cover Ozempic for weight loss alone. The original Part D statute excluded "agents when used for anorexia, weight loss, or weight gain" from the standard benefit, which is why anti-obesity medications including off-label Ozempic for weight loss have historically been ineligible ^[4]. CMS clarified in March 2024 that Part D may cover anti-obesity medications when they are approved by the FDA for an additional medically accepted indication (for example, Wegovy when used for cardiovascular risk reduction in adults with obesity and established cardiovascular disease). That clarification does not apply to off-label Ozempic for weight loss in a patient without T2D.

Medicare cannot cover Ozempic for prediabetes either. Part D coverage requires the drug be used for an FDA-approved indication, and prediabetes is not one.

Medicaid

Medicaid coverage of Ozempic for T2D is widespread across states, with most state programs covering Ozempic on their preferred drug list or with prior authorization. Step therapy with metformin is standard. State-by-state variation exists in the PA criteria, the preferred GLP-1 within each state's contract, and the documentation thresholds. Call your state Medicaid managed care plan's pharmacy line for specifics.

Medicaid coverage for Ozempic for weight loss is rare. A handful of states cover anti-obesity medications under specific criteria for Wegovy or Saxenda, but coverage for off-label Ozempic for weight loss is not standard in any state we have surveyed.

TRICARE and the VA

TRICARE covers Ozempic for type 2 diabetes through the TRICARE Pharmacy Program, with prior authorization. Coverage for weight loss is restricted; Wegovy is the on-label option and is covered for specific criteria including BMI thresholds.

The VA covers Ozempic for T2D through the VA National Formulary with prior authorization. Veterans should work with their VA primary care provider; non-VA prescriptions are processed differently and typically require additional steps.

Common questions

Does insurance cover Ozempic for weight loss?

Almost never. Most plans exclude off-label weight loss use of Ozempic. If weight loss is the goal and you do not have type 2 diabetes, the on-label path is Wegovy, which some plans cover with a separate prior authorization.

What diagnosis will cover Ozempic?

Type 2 diabetes (ICD-10 E11.x) is the diagnosis that unlocks coverage. Prediabetes, obesity, insulin resistance, and PCOS do not. Cardiovascular risk reduction in patients with both T2D and established cardiovascular disease is also a covered indication.

Does Medicare cover Ozempic?

Medicare Part D covers Ozempic for type 2 diabetes with prior authorization. Medicare cannot cover Ozempic for weight loss alone or for prediabetes, because Part D excludes weight-loss agents and requires an FDA-approved indication.

Does Medicaid cover Ozempic?

Most state Medicaid programs cover Ozempic for type 2 diabetes after prior authorization, with step therapy through metformin. Medicaid coverage for weight loss varies by state and is uncommon for Ozempic specifically.

My insurance denied Ozempic. What do I do first?

Read the denial letter and identify the specific reason cited. Internal appeals address the cited reason directly, with documentation. If the reason is step therapy, submit the prior medication history. If the reason is insufficient documentation, submit the labs and chart notes. If the reason is off-label use, switch the conversation to Wegovy if weight loss is the goal.

How do I appeal an Ozempic insurance denial?

Submit a written internal appeal within the deadline (typically 60 to 180 days) that responds to the specific denial reason with supporting documentation. Ask your prescriber to request a peer-to-peer review with the insurer's medical director. If the internal appeal fails, request external review through your state insurance department.

What are the prior authorization criteria for Ozempic?

Most plans require a confirmed type 2 diabetes diagnosis (A1C at or above 6.5%), a documented trial of metformin or a documented contraindication, age 18 or older, and a prescription from an appropriately credentialed prescriber. Some plans add an A1C threshold (often above 7.0%) while on prior therapy.

Can a nutritionist prescribe Ozempic?

No. Nutritionists and registered dietitians do not have prescriptive authority for medications. A physician, nurse practitioner, or physician assistant must write the prescription.

Will my doctor prescribe Ozempic?

A doctor will prescribe Ozempic when there is a clinical indication that supports it, typically type 2 diabetes with inadequate glycemic control on first-line therapy. Bring your A1C, your medication history, and your insurance card to the visit and ask directly.

Does Blue Cross Blue Shield cover Ozempic?

Most BCBS plans cover Ozempic for type 2 diabetes with prior authorization. Coverage for weight loss is rare across BCBS plans, and several BCBS affiliates reduced or removed Wegovy coverage in 2024 to 2025, so confirm current benefits with member services.

Does Kaiser Permanente cover Ozempic?

Kaiser covers Ozempic within its integrated formulary for type 2 diabetes, with prior authorization handled internally. Kaiser does not generally cover GLP-1 medications for weight loss.

Does UnitedHealthcare cover Ozempic?

UnitedHealthcare covers Ozempic for type 2 diabetes with prior authorization on most plans, with step therapy through metformin. Wegovy coverage exists on some employer-sponsored UnitedHealthcare plans but is not universal.

Does Cigna cover Ozempic for weight loss?

Cigna covers Ozempic for type 2 diabetes with prior authorization. Coverage for off-label weight loss is not standard. Cigna covers Wegovy on some plans as part of a weight-management benefit.

Does the VA cover Ozempic?

Yes, the VA covers Ozempic for type 2 diabetes through the VA National Formulary with prior authorization. Veterans should work through their VA primary care provider to initiate the prescription.

Does TRICARE cover Ozempic?

TRICARE covers Ozempic for type 2 diabetes with prior authorization. Weight-loss use is generally not covered through TRICARE; Wegovy is the on-label path with its own coverage criteria.

What if I am pre-diabetic and want Ozempic?

Ozempic is not approved for prediabetes and insurance will not cover it for that indication. The covered paths are either lifestyle modification with monitoring for progression to T2D, or Wegovy for weight management if BMI criteria are met and the plan covers anti-obesity medications.

What this article does not cover

This page is about Ozempic coverage specifically. Wegovy coverage, while related, has its own prior authorization pathway and its own list of covering plans, and it deserves its own page. So do the comparisons between Ozempic and Mounjaro for coverage strategy, and the question of whether compounded semaglutide is legally available in your state in 2026. Use the search or the sidebar to find those. The framework on this page (confirm the diagnosis, get the right prescriber, win the PA, appeal the denial, switch the path if you must) generalizes to every GLP-1 coverage fight you will have.